The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma

Table 2 Univariate and Multivariable Cox model for disease-free survival

Variables	Disease-free survival
Variables	Univariate analyses Hazard Ratios (95% CI)	P	Multivariate analyses Hazard Ratios (95% CI)	P
Age	1.927(0.938–3.961)	0.074	1.271(0.555–2.910)	0.571
Gender	0.985(0.488–1.990)	0.967
ECOG status	1.549(0.746–3.128)	0.24
Tobacca use	1.152(0.578–2.293)	0.688
Hematuria	0.703(0.334–1.478)	0.353
Tumor size	1.041(0.523–2.072)	0.908
Grade	1.257(0.299–5.282)	0.754
Pathological stage
T2	1.000(Ref.)		1.000(Ref.)
T3	3.056(1.299–7.191)	0.01	2.968(1.197–7.357)	0.019
T4	50.561(10.038–254.680)	< 0.001	26.557(3.497-201.692)	0.002
Lymph node metastasis	3.293(1.322–8.208)	0.011	1.405(0.407–4.859)	0.591
Location	0.676(0.340–1.345)	0.265
Comorbidity number	2.565(1.276–5.154)	0.008	2.316(1.069–5.017)	0.033
eGFR	1.413(0.700-2.855)	0.335
Postoperative management	0.367(0.169–0.796)	0.011	0.387(0.164–0.911)	0.03

ISSN: 1471-2407